SpectraCure AB Quarterly Report (1 July to 30 September) 2019

Third quarter (1 July – 30 September 2019)

  • Other income amounted to TSEK 692 (215).
  • Profit after tax amounted to TSEK -3 054 (-1 922).
  • Corresponding to SEK -0,04 (-0,03) kr per share before and after diluted earnings.
  • Operating cash flow was TSEK -3 072 (-2 640).
  • Cash as of 30 September amounted to TSEK 25 421 (2 185) TSEK.
  • Equity ratio: 81 (85)%.

1 January – 30 September 2019

  • Other income amounted to TSEK 2 005 (902).
  • Profit after tax amounted to TSEK –9 979 (-8 572).
  • Corresponding to SEK -0,12 (-0,13) kr per share before and after diluted earnings.
  • Operating cash flow was TSEK -6 648 (-7 058).

 

For further information, please contact:
 

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46(0) 8 503 000 50 

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on November 12th, 2019 at 2 p m.

Press release "SpectraCure AB Quarterly report 1 July to 30 September 2019 ​​​​​​"
SPC Q3 2019

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope